Overview

Zalutumumab in Patients With Non-curable Head and Neck Cancer

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate if zalutumumab in combination with Best Supportive Care (BSC) is superior to BSC in non-curable patients with head and neck cancer
Phase:
Phase 3
Details
Lead Sponsor:
Genmab
Treatments:
Antibodies, Monoclonal
Zalutumumab